Bortezomib, a potent and reversible proteasome inhibitor, affects the myeloma cell and its microenvironment, resulting in downregulation of growth and survival signaling pathways and durable responses in patients with relapsed and refractory myeloma.
Introduction
Prognostic factors may be useful to help select patients with multiple myeloma who are more likely to benefit from certain types of therapy. Factors that have been identified as predictive of a poor outcome in patients with multiple myeloma at presentation are listed in Table 1 . [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] At relapse, adverse prognostic factors have included increased age, 13, 14 elevated creatinine ≥ 2 mg/dL, 14 chromosome 13 deletion or other cytogenetic abnormalities, [13] [14] [15] increased plasma-cell labeling index, 15 and elevated levels of β 2 -microglobulin and C-reactive protein. 13, 15 Bortezomib, a potent, specific, and reversible inhibitor of the proteasome, offers a novel approach to the treatment of multiple myeloma. 16 In an open-label, phase 2 clinical trial (SUMMIT), 202 patients with relapsed and refractory myeloma were treated with bortezomib. 17 Durable responses were reported in this heavily pretreated population who had received a median of 6 prior therapies. The response rate (complete response [CR] + partial response [PR] ) was 27%, and the median time to response (TTR) was 1.3 months (~ 2 cycles). 17 With extended follow-up, the median duration of response (DOR) was 12.7 months, median time to progression (TTP) among all patients was 7.0 months, and median overall survival (OS) was 17.0 months. 18 New therapies for myeloma with novel mechanisms of action may have the ability to change the course of the disease or be active in patients in whom other therapies fail.
Importantly, their use should be prioritized in patients most likely to benefit from them.
The objective of this study was to perform an analysis of baseline demographic and
For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From disease parameters to determine their value in predicting outcome for patients with relapsed and refractory multiple myeloma being treated with bortezomib. Univariate analyses were used to identify single factors that appeared to be associated with outcome, then multivariate analyses were used to eliminate factors that may confound a univariate analysis.
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Methods
Patients
Patients with multiple myeloma who had relapsed following initial chemotherapy and who had been refractory to their most recent salvage chemotherapy were enrolled into the SUMMIT trial, the methodology of which has been previously published. 17 The main inclusion criteria were Karnofsky performance score (KPS) of ≥ 60, hepatic transaminases within 3 times the upper limit of normal (ULN), serum total bilirubin concentration ≤ 2 × ULN, creatinine clearance of > 30 mL/min (exceptions were allowed for ≤ 30 but > 10 mL/min if due to significant myelomatous involvement of the kidney), platelet count of ≥ 50 × 10 9 /L (or ≥ 30 × 10 9 /L if extensive bone marrow infiltration by myeloma was present), hemoglobin level of ≥ 8 g/dL, and an absolute neutrophil count of ≥ 500/µL. All patients provided written informed consent before entering the study, which was performed in accordance with the Declaration of Helsinki and approved by the institutional review board at each participating center. The response rate (CR + PR) to bortezomib alone was examined in 193 evaluable patients, because 9 of the 202 patients enrolled into the SUMMIT trial were excluded from the intent-to-treat population for efficacy analyses. These patients were excluded because they were enrolled in the study with nonmeasurable disease and a priori the statistical analysis plan specified that only cases with measurable disease would be included in the intent-to-treat population because the internal review committee could not assess response. The DOR was assessed only in patients who responded to bortezomib alone (n = 53). The TTR and TTP were assessed for patients receiving bortezomib alone, whereas OS was assessed for all patients, regardless of the addition of dexamethasone. 
Statistical analyses
In the univariate analysis assessing response rate (CR + PR), Fisher's exact test was performed for categorical factors, and logistic regression was performed for continuous variables (β 2 -microglobulin level, serum albumin level, platelet count, and C-reactive protein level). In the univariate analysis assessing TTR, DOR, TTP, and OS, the Cox proportional hazards model was applied to calculate a hazard ratio to determine the relative risk of an event at any point in time associated with a 1-unit change in the variable. A hazard ratio greater than 1 indicates increased risk, whereas a ratio less than 1 indicates decreased risk. In the Cox regression analyses assessing TTR, TTP, and OS, a backward elimination method was used to derive the final analysis model. In the analysis of DOR (n = 53), a forward stepwise model selection method was used.
For
org From
In the multivariate analysis assessing response rate, logistic regression was performed for all factors to determine the relative contribution of each in predicting response. All factors were analyzed in a stepwise model selection procedure to determine a minimal set of prognostic factors. In the multivariate analysis assessing TTR, DOR, TTP, and OS, the Cox proportional hazards model was used to analyze all factors to determine the relative contribution of each factor. All factors were analyzed through a model selection procedure to determine a minimal set of prognostic factors. A P value < .05 was considered statistically significant, and a value ≥ .05 but < .10 was considered marginally significant.
Results
The 202 patients enrolled in SUMMIT had been heavily pretreated with a median of 6 previous therapies (range, 2-15), and 91% were refractory to their last therapy prior to bortezomib. Previous therapy included steroids in 99.5%, alkylating agents in 92%, thalidomide in 83%, anthracyclines in 81%, and stem cell transplantation in 64%. Ninetytwo percent of the patients were treated with 3 or more therapies, excluding stem cell transplantation. 17 
Response rate
Of 202 patients, 193 patients had measurable disease and were included in the analyses of response to bortezomib monotherapy. The response rate (CR + PR) was 27% (53 of 193 patients). 17 In the univariate analysis, the only factors that were associated with a significantly lower response to bortezomib were bone marrow plasma cell infiltration > 50% compared with ≤ 50% (20% vs 35%, P = .030) and abnormal cytogenetics responses in patients with light-chain disease were CR, whereas 11 of the 44 responses in patients with heavy-chain disease were CR. Marginal significance was noted for age ≥ 65 (19% vs 32%, P = .064) and white race (24% white vs 48% black and 33% other, P = .064) The response rate to bortezomib was not significantly affected by sex, body surface area, KPS, number or type of prior therapy, myeloma type, chromosome 13 deletion, and hemoglobin or β 2 -microglobulin concentration (Table 2) . By multivariate analysis (Table   3) , only 2 factors were significantly associated with a lower response rate to bortezomib after stepwise selection analysis: age ≥ 65 years (P = .03) and bone marrow plasma cell infiltration > 50% (P = .03).
TTR, DOR, TTP, and OS
By univariate analysis, the only factors associated with a longer TTR were older age (P = .042) and abnormal cytogenetics (P = .047) but not chromosome 13 deletion (Table 4) .
By multivariate analysis, however, abnormal cytogenetics dropped out, whereas older age (P = .009) and bone marrow plasma cells > 50% (P = .021) were found to be associated with a longer TTR. An increased C-reactive protein concentration was marginally significant by multivariate analysis (P = .0501).
Factors were assessed to determine their association with DOR in this patient population.
Previous treatment with thalidomide (P = .033), hypoalbuminemia (P = .001), low KPS (P = .004), and abnormal cytogenetics (P = .035) but not chromosome 13 
with a shorter DOR in the univariate analysis. Factors that remained significantly associated with a shorter DOR in the multivariate assessment were hypoalbuminemia (P = .003) and low KPS (P = .01).
Likewise, factors associated with a shortened TTP were assessed by univariate analysis.
Patients with bone marrow plasma cell infiltration > 50% (P = .009), increased β 2 -microglobulin concentration (P = .02), thrombocytopenia (P = .025), increased Creactive protein concentration (P = .037), anemia (P = .005), abnormal cytogenetics (P < .0001), higher stage (P = 0.024), and chromosome 13 deletion (P = .013) had a shorter TTP. Factors associated with a shortened TTP that remained significant when assessed by multivariate analysis were increased C-reactive protein concentration (P = .011) and abnormal cytogenetics (P = .02), but not chromosome 13 deletion.
Although many factors were found to be associated with a shorter OS by univariate analysis, only 4 were significantly associated with shorter survival in the multivariate analysis: bone marrow plasma cells > 50% (P = .028), hypoalbuminemia (P < .001), thrombocytopenia (P = .024), and low KPS (P = .034).
Discussion
Bortezomib can induce objective responses in patients with relapsed and refractory multiple myeloma. The results of the multivariate analysis confirmed that the following baseline factors did not influence clinical response rate with bortezomib: the number or type of previous therapies, sex, body surface area, chromosome 13 deletion, and hemoglobin and β 2 -microglobulin concentrations. Whilst the overall response rate was Therefore, although it appears that patients with light-chain disease achieved a higher CR rate, this conclusion is difficult to confirm. Conversely, the lack of effect of chromosome 13 abnormalities on response to bortezomib is noteworthy, because this cytogenetic abnormality has been shown to be an important negative prognostic factor of response in relapsed myeloma treated with certain other agents. 15 Advanced age has been associated with a poor response to treatment in relapsed multiple myeloma treated with thalidomide. 13 Age was also predictive of response to bortezomib but did not affect DOR, TTP, or OS. These results suggest that age alone should not represent a barrier to treatment with bortezomib. Although older patients could take longer to respond, the data suggest that elderly patients who do respond could achieve benefit similar to that of younger patients with respect to DOR, TTP, and OS.
The other significant factor in the multivariate analysis of response rate was greater than 50% plasma cell infiltration in the bone marrow. In general, factors that correlate with high tumor burden (ie, hypoalbuminemia, bone marrow plasma cell infiltration > 50%, and thrombocytopenia) were associated with a shorter DOR and OS with bortezomib. last therapy prior to enrolling in the study. 17 The importance of prognostic factors in the pretreatment evaluation of myeloma has gained even more significance with the creation of the new International Staging System (ISS). 19 The new system uses only 2 factors for staging patients at diagnosis: serum albumin as a correlate of rapid myeloma growth, and β 2 -microglobulin as a marker of tumor burden. In the univariate analysis, shorter DOR and OS were individually associated with lower albumin, and shorter TTP and OS were associated with higher β 2 -microglobulin, but response rate, TTR, and DOR with bortezomib treatment were independent of stage as defined by the ISS using albumin and β 2 -microglobulin. In the univariate analysis, stage was predictive of TTP and OS.
The ability to generally predict response, TTR, DOR, TTP, and OS is meaningful for the physician and the patient in making treatment decisions. In a phase 3 randomized trial, APEX, in which bortezomib therapy was compared with high-dose dexamethasone in patients who had received 1 to 3 prior lines of therapy, bortezomib demonstrated significantly greater benefit in terms of TTP and OS at the preplanned interim analysis, resulting in an independent committee decision to recommend early closure of the
arm and allow all patients access to bortezomib. 21 Prognostic factors will be evaluated in this study as well. In addition, the prognostic value of certain genetic markers will be further explored in APEX.
A fascinating research focus derived from this work has been the exploration of genetic markers that may aid in identifying patients with a high potential for response to specific therapies. 22 Genetic markers from pretreatment bone marrow aspirates of myeloma cells are being studied by microarray analysis in subsets of patients treated with bortezomib in phase 2 and 3 studies to validate this methodology as a promising tool in targeted therapy. Initial research from SUMMIT has shown the feasibility of this approach, and preliminary data suggest that a highly significant gene expression signature can distinguish responders from nonresponders. 23 These data may provide yet another valuable method to identify patients with the potential to obtain clinical benefit from bortezomib.
Positive clinical outcome in patients with relapsed and refractory multiple myeloma treated with bortezomib appeared to be independent of many patient and disease factors historically considered to be adverse prognostic factors in myeloma. Importantly, the type or number of prior therapies and an increased baseline β 2 -microglobulin were not associated with a poor response to bortezomib or unfavorable changes in time-to-event parameters. Although older patients had a lower response rate to bortezomib in this study, their duration of response and survival were not negatively affected.
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Importantly, pharmacogenomics in conjunction with these clinical factors may provide further insight not only into response to bortezomib but also into rational designs for combinations. • Age ≥ 65 years .03
• Bone marrow plasma-cell infiltration > 50% .03
Time to response (longer)
• Age ≥ 65 years .009
• Bone marrow plasma-cell infiltration .021
Duration of response (shorter)
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Time to progression (shorter)
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